Renzapride - Ambrose Healthcare
Alternative Names: ATL-1251; AZM 112; BRL-24924; Renzapride hydrochlorideLatest Information Update: 27 Feb 2025
At a glance
- Originator GlaxoSmithKline
- Developer Alizyme; Ambrose Healthcare; Atlantic Healthcare; GlaxoSmithKline
- Class Antifibrotics; Antiparkinsonians; Benzamides; Gastrokinetics; Heterocyclic bicyclo compounds; Irritable bowel syndrome therapies; Skin disorder therapies; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists; Serotonin 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cystic fibrosis
- Discontinued Diabetic gastroparesis; Gastro-oesophageal reflux; Gastroparesis; Irritable bowel syndrome; Parkinson's disease; Systemic scleroderma
Most Recent Events
- 27 Feb 2025 Discontinued - Phase-I for Gastroparesis in United Kingdom (PO)
- 27 Feb 2025 Discontinued - Phase-I for Parkinson's disease in United Kingdom (PO)
- 27 Feb 2025 Discontinued - Phase-I for Systemic scleroderma in United Kingdom (PO)